0
Article ? AI-assigned paper type based on the abstract. Classification may not be perfect — flag errors using the feedback button. Tier 2 ? Original research — experimental, observational, or case-control study. Direct primary evidence. Detection Methods Environmental Sources Food & Water Human Health Effects Nanoplastics Policy & Risk Sign in to save

Microplastic Neurotoxicity-bbb-targeted Pharmacotherapy

Zenodo (CERN European Organization for Nuclear Research) 2026
Siri Varma M.*1, Kalpana P.1, Kavya T.1, Shivani Polenwar2

Summary

**TLDR:** This research review summarizes studies showing that tiny plastic particles from contaminated air, water, and food may damage the protective barrier around our brain, potentially leading to memory problems and other brain issues. The good news is that scientists have identified several existing medications that might help protect the brain from plastic particle damage, though more research is needed to confirm these treatments work in humans.

Body Systems
Study Type Environmental

Microplastic and nanoplastic exposure is now a plausible biological risk due to widespread contamination of air, drinking water, and food systems. Preclinical evidence increasingly indicates that micro-/nanoplastic particles may enter systemic circulation and interact with the neurovascular unit, weakening blood–brain barrier (BBB) integrity and promoting central nervous system (CNS) injury. Proposed mechanisms include tight junction remodeling, endothelial oxidative injury, mitochondrial dysfunction, microglial activation, and NLRP3 inflammasome–driven cytokine release, which collectively undermine synaptic plasticity and behavior. Because microplastic neurotoxicity involves multiple converging pathways, a rational therapeutic strategy should integrate BBB stabilization, oxidative stress control, neuroinflammation suppression, and synaptic rescue. This review consolidates current evidence on (i) exposure routes and systemic distribution, (ii) BBB penetration and disruption mechanisms, (iii) downstream molecular cascades associated with cognitive and affective impairment, and (iv) pharmacotherapeutic countermeasures with repurposing potential, including N-acetylcysteine, minocycline, memantine, retinoid-based BBB modulators, and selective inflammasome inhibitors. Finally, research gaps and a translational roadmap are presented, emphasizing standardized particle characterization, biomarker-guided outcome assessment, and targeted studies in high-exposure occupational cohorts.

Share this paper